A 38-year-old woman presents to the gynaecology outpatient department with a 2-year history of heavy menstrual bleeding and lower abdominal pain. She reports soaking through 8–10 pads per day during menses, lasting 7 days. On examination, the uterus is firm, irregular, and enlarged to about 14 weeks size. Pelvic ultrasound confirms multiple intramural and submucosal fibroids, the largest being 4 cm. She is nulliparous and desires future pregnancy. Her haemoglobin is 9.2 g/dL. What is the most appropriate first-line medical management for her menorrhagia?

Explanation

## Management of Fibroid-Related Menorrhagia in a Nulliparous Woman ### Clinical Context This patient has symptomatic fibroids with menorrhagia, anaemia (Hb 9.2 g/dL), and a strong desire for future fertility. The key question is the **most appropriate first-line medical management** for her menorrhagia. ### Why Tranexamic Acid is the Correct First-Line Medical Option Here **Key Point:** Per NICE guideline NG88 (Heavy Menstrual Bleeding, 2018) and RCOG guidelines, **tranexamic acid** is recommended as a first-line non-hormonal medical treatment for heavy menstrual bleeding when an intrauterine device is not appropriate or acceptable. **High-Yield:** In this specific clinical scenario, the LNG-IUD is **contraindicated or not appropriate** because: - The patient has **submucosal fibroids** — submucosal fibroids distort the uterine cavity and are a recognised contraindication/impediment to IUD insertion (WHO MEC Category 3–4 for distorting cavity) - The stem explicitly states **multiple intramural AND submucosal fibroids** with a uterus enlarged to 14 weeks — this degree of cavity distortion makes LNG-IUD placement unreliable and potentially ineffective - NICE NG88 explicitly states LNG-IUD should not be inserted if the uterine cavity is distorted **Tranexamic acid** (antifibrinolytic): - Reduces menstrual blood loss by 40–60% in fibroid-related menorrhagia - Non-hormonal — does not affect ovulation or fertility - Safe for use in women desiring pregnancy - Dose: 1.3 g (or 1 g) three times daily during menses — as stated in option B - First-line per NICE NG88 when LNG-IUD is contraindicated ### Why Other Options Are Incorrect | Option | Rationale | |--------|-----------| | **GnRH agonist → hysterectomy** | Hysterectomy is inappropriate in a nulliparous woman desiring future pregnancy; GnRH agonists are preoperative adjuncts, not first-line medical therapy | | **Myomectomy + ART** | Surgical option; not first-line medical management; reserved for failure of medical therapy or immediate fertility planning | | **LNG-IUD** | Contraindicated with submucosal fibroids causing uterine cavity distortion (WHO MEC 3–4); insertion unreliable in a uterus enlarged to 14 weeks with multiple fibroids | ### Clinical Pearl **NICE NG88 Algorithm:** For HMB with fibroids — if uterine cavity is not distorted, LNG-IUD is first-line. If cavity IS distorted (submucosal fibroids, large uterus), non-hormonal options (tranexamic acid, NSAIDs) or hormonal tablets (norethisterone, combined OCP) are first-line medical alternatives. Tranexamic acid is the preferred non-hormonal choice preserving fertility. **Reference:** NICE Guideline NG88 (Heavy Menstrual Bleeding: Assessment and Management, 2018); Shaw RW, Luesley D, Monga A — *Gynaecology*, 4th ed.; RCOG Green-top Guideline No. 62. **Key Point:** The presence of submucosal fibroids with cavity distortion is the critical detail that makes LNG-IUD inappropriate and tranexamic acid the correct first-line medical answer in this vignette.